CA
NZ
UK
AU
IND
US
Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …
CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.
Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) for the treatment of post-partum depression (PPD) in adults following childbirth. The decision makes ZURZUVAE the first and only treatment specifically indicated for PPD in the European …
NovoCure Limited (NASDAQ: NVCR),a medical equipment company specializing in tumor treating fields (TTFields) devices for solid tumor cancers, currently holds a consensus analyst rating of"Moderate Buy,"according to MarketBeat Ratings. This consensus is derived from seven analysts covering the stock, with four recommending a buy …
Tourmaline Bio, Inc. (NASDAQ: TRML) operates as a clinical biotechnology company focused on developing therapies for immune and inflammatory diseases. Its lead asset, TOUR006, is a human anti-IL-6 monoclonal antibody designed to selectively bind interleukin-6, a proinflammatory cytokine implicated in various autoimmune and inflammatory …
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has received an upgrade from Wall Street Zen, moving from a“Sell” ratingto a“Hold” ratingin its latest research note issued Wednesday. This change reflects a more neutral stance on the company’s near-term performance after previously negative sentiment.
CAMP4 Therapeutics Corporation (Nasdaq:CAMP), a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics, announced that it has entered into definitive securities purchase agreements with institutional and accredited investors for up to$100 million in gross proceedsthrough a private placement.
Insight Molecular Diagnostics, Inc. (Nasdaq:IMDX) announced that it has begun actively enrolling patients in its clinical trial to evaluate GraftAssureDx, its next-generation kitted transplant rejection test. Last week, the first patient was enrolled, marking a key milestone in the study. The official clinical trial …
Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company developing therapies for autoimmune, inflammatory, and fibrotic diseases, announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application. The approval allows the company to advance PALI-2108, a first-in-class …
AC Immune SA (NASDAQ: ACIU) has announced a strategic restructuring aimed at streamlining operations and concentrating resources on its highest-value programs. The plan includes a 30% workforce reduction and a narrowed focus on three clinical-stage active immunotherapy programs, along with small molecule programs targeting …
Please wait processing your request...